ProtonIntel

Hyperkalemia (high potassium) affects more than 3.7M Americans. Chronic Kidney Disease is the main cause & heart attacks are the main effect. Proton Intelligence is building the first real-time, on-demand potassium monitoring wearable

Based based in Canada, ProtonIntel works in biopharma, founded in 2020.

Profile

Protonintel provides continuous, real-time, and accurate biomarker monitoring to better manage chronic disease and save lives. The ProtonPetal will be the only solution to provide accurate and real-time potassium (K+) measurements in the interstitial fluid of the skin continuously for heart and kidney care. Data from the ProtonPetal can be monitored by clinicians and end users to effectively use and manage medications, diet, or other treatment options to improve the health of individuals.

Within the biopharma space, the company focuses on its core offering rather than a broad product line.

The company is recorded as being based in Canada.

It is recorded at the SOSV portfolio company stage.

The company reports a headcount in the 11-50 range.

It has disclosed roughly $1.9M in funding.

Website: protonintel.com